Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Metastatic Castration Resistant Prostate Cancer
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male
  • Other Inclusion Criteria:
    1. Histologically- or cytologically-confirmed diagnosis of metastatic prostate adenocarcinoma
    2. Patients must have a positive PSMA scan as determined by an FDA approved PSMA PET scan
    3. Patients must have prior orchiectomy and/or ongoing androgendeprivation therapy and a castrate level of serum testosterone

You may not be eligible for this study if the following are true:

    1. Receiving other anti-cancer agent or device, or participating in other clinical trial, within 28 days of first dose of study treatment
    2. PSMA-negative metastatic lesions in lymph node, bone or soft tissue
    3. Symptomatic brain metastasis, symptomatic cord compression, or clinical or radiological findings indicative of impending cord compression



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.